Can you sell a Korean sunscreen in the US? FDA rules and your options

Check a Korean sunscreen against FDA's monograph, see what the 2026 bemotrizinol order changes, and compare six US options with a worked example.

A white sunscreen tube with a coral cap on sunlit linen under leaf shadows, a swatch of cream on a glass slide, sunglasses, a navy straw hat and a blank card.

Can you sell a Korean sunscreen in the US as it is?

Say you make a sun cream that sells well in Korea. A US retailer asks when it can ship. You ask your maker for the filter list, and it shows four UV filters. The cream is invented, but we’ll run it through the US rules later in this article.

You can sell a Korean sunscreen in the US as it is only if the formula already fits FDA’s sunscreen rules. The US treats sunscreen as an over-the-counter drug, meaning one sold without a prescription. Without an approved application, FDA’s sunscreen monograph (M020) must allow four things. These are every UV filter, its strength, each pairing of filters and the dosage form. The SPF test and the label must follow the monograph too.

A monograph is FDA’s published rulebook. It says which ingredients, strengths, tests and label wording a product type can use without an approved application. A Korean formula with a filter outside that list needs a US version or another pathway.

This article covers the US side only. We didn’t check Korean rules. A product that’s legal and tested in Korea has no automatic standing with FDA. FDA’s own consumer page says some countries regulate sunscreens as cosmetics. So a label from abroad can differ from a US label.

We checked every rule below against FDA and Federal Register pages on November 10, 2026. This is general information, not legal advice. Ask a US regulatory specialist to confirm the pathway for your formula.

Sources for this sectionSource: FDA, Sunscreen: How to Help Protect Your Skin from the Sun

Why does the US treat sunscreen as a drug?

FDA states that sunscreens are regulated as drugs in the United States. The category follows intended use, meaning what the product is sold to do. FDA says three things can show that use. They are claims, how consumers see the product, and ingredients with a well-known therapeutic use.

Moisturizers and makeup sold with sun-protection claims are both cosmetics and drugs. They must meet the rules for both. A sunscreen sold without an approved application must conform to the OTC monograph. So your sun cream is a drug in the US, whatever it’s called at home.

Our earlier article on why sunscreen changes the rules explains how intended use decides the category. It doesn’t list the monograph’s ingredients or compare your pathways. This article does both.

Sources for this sectionSource: FDA, Is It a Cosmetic, a Drug, or Both?

What must a sunscreen meet to sell without an approved application?

FDA’s monograph M020 sets five conditions, and a formula must meet all of them. Its current text took effect on August 9, 2026. You can check the first two with just your maker’s filter names and percentages.

  • Each UV filter must be on the list below, at or under its maximum strength.
  • You can combine filters only in the pairings section M020.20 allows. The finished SPF must be at least twice the number of filters in the combination.
  • SPF must be measured with FDA’s test. It uses human volunteers, with enough subjects for at least 10 valid results. Each one gives written informed consent. A product may say “Broad Spectrum SPF” only if its mean critical wavelength is 370 nm or more. That’s a lab measure of how broad the UV protection is.
  • The dosage form, meaning the kind of product, must be oil, lotion, cream, gel, butter, paste, ointment, stick, spray or powder. For bemotrizinol, powder and propellant aerosol are out. A sunscreen in another form, such as a shampoo or body wash, may be sold only with an approved application or an FDA order. The monograph also applies the general conditions in 21 CFR 330.1.
  • The label must use the wording in section M020.50. That includes the sunscreen statement of identity and the Uses, Warnings and Directions text. It also includes “Water Resistant (40 minutes)” or “(80 minutes)” where tested. Terms such as sunblock, sweatproof and waterproof misbrand the product.

FDA monograph M020: sunscreen active ingredients and maximum strengths in the text effective August 9, 2026

Active ingredientMaximum strength
Aminobenzoic acid (PABA)15 percent
Avobenzone3 percent
Bemotrizinol6 percent
Cinoxate3 percent
Dioxybenzone3 percent
Ensulizole4 percent
Homosalate15 percent
Meradimate5 percent
Octinoxate7.5 percent
Octisalate5 percent
Octocrylene10 percent
Oxybenzone6 percent
Padimate O8 percent
Sulisobenzone10 percent
Titanium dioxide25 percent
Trolamine salicylate12 percent
Zinc oxide25 percent
Sources for this sectionSource: FDA, OTC Monograph M020 (effective August 9, 2026)

What changed in FDA’s sunscreen rules in 2026?

Bemotrizinol joined FDA’s list of allowed sunscreen filters in 2026. FDA announced the change on June 9, 2026. Final Administrative Order OTC000039 is dated June 10, 2026. It was corrected on August 10 for typographical errors. FDA calls it the first new active ingredient added to the monograph since the late 1990s.

The order allows bemotrizinol up to 6 percent. That covers adults and children 6 months and older. The finished product must reach at least SPF 2. The filter is limited to oil, lotion, cream, gel, butter, paste, ointment, stick and spray. A spray must be made without propellant, or with the propellant isolated from the formula. FDA didn’t find data to support powders or propellant-based aerosols.

The order also grants exclusivity, meaning only certain companies may sell the filter for a set time. It authorizes only DSM Nutritional Products LLC, which requested the change, to market bemotrizinol sunscreens for 18 months. Its licensees, assignees or successors in interest may do so too. The clock counts from the order’s effective date and from the date DSM may lawfully market.

FDA’s pages don’t give an end date. Until counsel confirms one, plan on needing DSM’s permission to use this filter.

On September 10, 2026, FDA issued a second order. It removes PABA and trolamine salicylate once it takes effect. Both still appear in the current text. The law sets the earliest effective date at one year after issuance. FDA says it knows of no sunscreen sold in the US that contains either.

A 2021 FDA proposal would change other conditions, including a maximum labeled SPF of 60+. It isn’t final. So check the date on any guide that lists allowed filters, because the list changed on August 9, 2026.

Sources for this sectionSource: FDA, Final Administrative Order OTC000039Source: Federal Register, notice of availability of Final Order OTC000039 (91 FR 35220, June 10, 2026)Source: FDA, FDA Expands Sunscreen Options for the First Time in 20 YearsSource: FDA, Questions and Answers on regulatory actions on OTC sunscreen

What are your options if your sunscreen formula doesn’t fit?

You have six routes when a formula doesn’t fit the monograph, and each one costs something. The table gives the main drawback of each and when it’s the right one.

Read the last column first. Say the sun cream is your hero product and the US is a main market. Then the table points to a US version with listed filters. Say other products can carry your first US year. Then launching without the sunscreen is the simpler route. And if your formula can’t be matched without bemotrizinol, you need permission from DSM or a licensee during the exclusivity period.

Six ways forward for a Korean sunscreen that does not match the monograph

OptionMain stepDrawbackChoose this if
Make a US version with listed filtersReplace unlisted filters, keep strengths and pairings inside M020, retest SPF and broad spectrum with FDA's method, relabel to section M020.50 and make it at an FDA-registered drug facilityA second formula to test, label and stock, which may feel different from the Korean versionThe sunscreen is your hero product and the US is a main market
Use bemotrizinol under licenseAsk DSM, or a licensee, whether you and your maker can use it, within the 6 percent and dosage-form limitsFDA's pages say nothing about licensing terms, so you depend on DSM's permission during the exclusivity periodYour formula cannot be matched without it and you can wait for terms
Wait for the exclusivity period to endLaunch other products and revisit when counsel confirms the end dateNo sunscreen sales, and FDA does not state the end dateSunscreen is not needed for your first US year
Ask FDA to add a new filterFile an OTC monograph order request. The bemotrizinol request was submitted on September 23, 2024 and finalized on June 10, 2026FDA's fiscal year 2027 fee for a request that adds an active ingredient is $614,608, due when you submit, and the exclusivity goes to the requesterYou own a filter that other brands would license
Seek an approved applicationA drug that does not conform to the monograph needs an application approved under section 505 of the FD&C ActWe did not research the cost or timeline. Ask a regulatory attorney before you commitThe formula cannot be changed and a US regulatory attorney supports this route
Launch without the sunscreenLead the US launch with products that are not drugsYour US range has no sunscreen until a later launchOther products can carry the first US year
Sources for this sectionSource: FDA, Final Administrative Order OTC000039 (exclusivity and effective date)Source: Federal Register, OTC Monograph Drug User Fee Rates for Fiscal Year 2027 (91 FR 48121)
Go deeperWhich K-beauty product should lead your US launch?

How do you check your own sunscreen formula?

Ask your maker for the full UV filter list, with the name and percentage of each. Then check three things in order. Is each filter on FDA’s list? Is each strength at or under the maximum? Is each pairing allowed?

Back to the invented sun cream from the start. The table below runs its four filters through those checks. It isn’t a real product. It’s there to show the method.

Result: the invented cream fails twice. One filter, ethylhexyl triazone, isn’t on the list. And avobenzone with zinc oxide isn’t a pairing M020 allows.

That’s our reading of section M020.20(a). The list in (a)(2) that includes avobenzone leaves out zinc oxide and titanium dioxide. The list in (a)(1) that includes them leaves out avobenzone.

A US version could drop the unlisted filter. It could keep avobenzone with octocrylene, or zinc oxide with octocrylene, and then be retested. You can’t know whether the retested formula reaches the same SPF and broad-spectrum result as the Korean one until the tests are run.

The worksheet below has the same steps for your own formula. It has a column for the evidence behind each answer.

Worked example: an invented Korean cream with four UV filters

Filter and strength (invented)On FDA's list?At or under the maximum?Pairing allowed?
Zinc oxide 10 percentYes, section M020.10(q)Yes, maximum 25 percentWith octocrylene, yes. With avobenzone, no
Octocrylene 6 percentYes, section M020.10(k)Yes, maximum 10 percentWith zinc oxide and with avobenzone, yes
Avobenzone 2.5 percentYes, section M020.10(b)Yes, maximum 3 percentWith zinc oxide, no
Ethylhexyl triazone 3 percentNoNot applicableNot applicable
Sources for this sectionSource: FDA, OTC Monograph M020, sections M020.10 and M020.20
Go deeperDownload the formula check worksheet (CSV)

What does selling sunscreen as a US drug require, and what does it cost?

Selling sunscreen as a US drug means your maker registers with FDA and follows drug manufacturing rules. FDA’s import page says foreign facilities must register and list their drugs if they manufacture, repack, relabel or salvage drugs. A drug must be made to current good manufacturing practice. It must follow the labeling rules in 21 CFR Part 201. It also needs either an approved application or to conform to an OTC monograph.

FDA also charges facility fees. Fiscal year 2027 runs from October 1, 2026 to September 30, 2027. For that year, FDA’s OTC monograph user fee notice sets two fees. An OTC monograph drug facility pays $47,891. A contract manufacturing facility pays $31,927. The lower fee applies where neither the owner nor an affiliate sells the drug directly to wholesalers, retailers or consumers in the US.

The fee is assessed on the facility’s owner. It covers facilities identified as OTC monograph drug facilities from January 1 to September 30, 2026. It’s due in two parts, on October 1, 2026 and February 1, 2027, if the funding arrives before those dates as FDA expects. Ask your maker whether it passes this cost on to you, and how.

A product that’s both a drug and a cosmetic, such as a moisturizer with SPF, isn’t listed separately under MoCRA, the federal cosmetics law. FDA’s cosmetic registration guidance says to identify it as both in the drug listing. A facility that also makes cosmetics that aren’t drugs must still register under MoCRA. The exception is where an exemption, such as the small-business exemption, applies.

The stakes are real. In March 2025, FDA sent a warning letter to a company selling a zinc oxide shampoo and body wash with sunscreen claims. The letter says that failing to correct the violation may lead to legal action, including seizure and injunction.

Sources for this sectionSource: FDA, Importing Over-the-Counter DrugsSource: Federal Register, OTC Monograph Drug User Fee Rates for Fiscal Year 2027 (91 FR 48121)Source: FDA, Registration and Listing of Cosmetic Product Facilities and Products (December 2024)Source: FDA warning letter to Waxhead Sun Defense Company (March 12, 2025)
Go deeperOur checklist for importing Korean beauty products into the US

What about SPF claims on a product that isn’t a sunscreen?

A sun-protection claim on a moisturizer or makeup makes it a drug as well as a cosmetic. Cushion compacts and foundation are examples. So the drug rules apply to that claim.

Watch the copy your team or a creator carries over from a Korean listing. An SPF number or the words UV protection can create a sun-protection claim in the US. FDA says claims on labeling, in advertising, on the Internet or in other promotional materials can show what a product is intended for.

So if your sun cream’s Korean page carries an SPF number, keep it out of US listings and creator briefs for now. Hold that language until a US regulatory specialist has reviewed the formula and the claim.

Dahna doesn’t give legal or regulatory advice. After your specialist decides what the product can say, we can write US product pages, listings and creator briefs inside those limits.

Sources for this sectionSource: FDA, Is It a Cosmetic, a Drug, or Both?

What should you do this week?

Start with your maker’s filter list. Then work through these steps in order.

All beauty and K-beauty marketing guides are on one page, including more on the steps before a US launch. If you want help planning the launch around the products you can sell first, see how Dahna works with K-beauty brands.

  • Ask your maker for the complete UV filter list, with names, strengths and the SPF test reports.
  • Check each filter, strength and pairing against the table and the worksheet.
  • Take SPF and UV claims out of US copy and creator briefs until a specialist has reviewed them.
  • Pick the option that fits, and ask a US regulatory attorney to confirm it for your formula.
  • Plan launch products that don’t depend on the sunscreen.

In summary

You can sell a Korean sunscreen in the US as it is only if every UV filter, strength, filter pairing and dosage form fits FDA’s sunscreen monograph. That monograph is FDA’s rulebook for selling a sunscreen without an approved application. If your formula misses on one point, the main choices are these. You can make a US version, license bemotrizinol, wait, or lead with other products.

Sources & further reading

  1. OTC Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, effective August 9, 2026 (checked November 10, 2026)U.S. Food and Drug Administration
  2. Final Administrative Order OTC000039, issued June 10, 2026, corrected August 10, 2026 (checked November 10, 2026)U.S. Food and Drug Administration
  3. Notice of availability of Final Order OTC000039 (bemotrizinol), 91 FR 35220, June 10, 2026 (checked November 10, 2026)Federal Register
  4. FDA Expands Sunscreen Options for the First Time in 20 Years, June 9, 2026 (checked November 10, 2026)U.S. Food and Drug Administration
  5. Sunscreen: How to Help Protect Your Skin from the Sun (checked November 10, 2026)U.S. Food and Drug Administration
  6. Questions and Answers: FDA's regulatory actions on over-the-counter sunscreen (checked November 10, 2026)U.S. Food and Drug Administration
  7. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) (checked November 10, 2026)U.S. Food and Drug Administration
  8. Importing Over-the-Counter Drugs (checked November 10, 2026)U.S. Food and Drug Administration
  9. Guidance for Industry: Registration and Listing of Cosmetic Product Facilities and Products, December 2024 (checked November 10, 2026)U.S. Food and Drug Administration
  10. Over-the-Counter Monograph Drug User Fee Rates for Fiscal Year 2027, 91 FR 48121, Docket FDA-2026-N-7559 (checked November 10, 2026)U.S. Food and Drug Administration, Federal Register
  11. Warning letter to Waxhead Sun Defense Company, March 12, 2025 (checked November 10, 2026)U.S. Food and Drug Administration, CDER
Published Topics
  • Regulatory
  • Market entry
Ana Yon
More by AnaAna on LinkedIn

Plan the US copy around what the product can claim.

Dahna does not give legal or regulatory advice. Once your regulatory specialist has decided what the product can say, Dahna can write the US product pages, listings and creator briefs inside those limits and plan the launch around the products you can sell first.

Explore content and creative productionSee how Dahna works with brands

This article is general information. It is not legal or regulatory advice.

Tell us your story

Share a little about your brand and what you need help with. We reply within 24 hours.

What do you sell, who do you want to reach, and what would you like to achieve?

Add details (optional)
What can we help with? (optional, choose any)